Advances in Preventive Cardiology Highlights from the ESC

WEBINAR

Advances in Preventive Cardiology Highlights from the ESC

Faculty: Christie Ballantyne, Deepak Bhatt, Peter Libby

Notification icon This webinar took place on 
http://www.vumedi.com/webinar/advances-in-preventive-cardiology-highlights-from-the-esc/

Program

Christie Ballantyne

Baylor College of Medicine, Houston, TX.

Anacetrapib reduces risk of serious cardiovascular events in high risk patients on statins (REVEAL)

Deepak Bhatt

Brigham and Women's Hospital, Boston, MA.

Rivaroxaban plus aspirin improves outcomes in stable cardiovascular disease (COMPASS)

Peter Libby

Brigham and Women's Hospital, Boston, MA.

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease (CANTOS)

Faculty:

  • Christie Ballantyne

    Baylor College of Medicine, Houston, TX.

  • Deepak Bhatt

    Brigham and Women's Hospital, Boston, MA.

  • Peter Libby

    Brigham and Women's Hospital, Boston, MA.

Release: 12/06/2017

Expiration: 12/08/2017

Location: Online

Requirements for successful completion: In order to receive credit, participants must view all audio-visual presentations and complete both the pre-test, post-test and evaluation form. Participants must score 100% on the activity post-test in order to receive credit. There are no pre-requisites for this activity. Course attendance verification forms are provided upon successful completion of the post-test and evaluation form. No partial credit will be given.

Target Audience: Physicians, residents and trainees, fellows, nurses, surgical techs, physical therapists, and other members of the allied health community whose scope of practice encompasses Cardiovascular.

Course Description: In this live webinar, expert Clinical Cardiology, Interventional Cardiology will present optimal operable techniques and treatment options to address Advances in Preventive Cardiology Highlights from the ESC. The webinar features time for interactive audience discussion and surgical case based scenarios.

Learning Objectives: Upon completion of this activity, participants should be better able to discuss:

  1. Discuss results of REVEAL trial
  2. Discuss results of COMPASS trial
  3. Discuss results of CANTOS trial

Credits: This lecture qualifies for 2 CME credit hours.

Cost: $0.0

Accreditation Statement: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of California, Irvine School of Medicine and VuMedi. The University of California, Irvine School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement: The University of California, Irvine School of Medicine designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty Disclosures: Dr. Christie Ballantyne discloses the following relevant financial relationships with a commercial interest: Abbott Diagnostic, Amarin, Amgen, Esperion, Ionis, Novartis, Pfizer, Regeneron, Roche Diagnostic, Sanofi-Synthelabo, NIH, AHA, ADA - Grants/Research Support. Abbott Diagnostics, Amarin, Amgen, Astra Zeneca*, Boehringer Ingelheim*, Eli Lilly, Esperion, Ionis, Matinas BioPharma Inc, Merck*, Novartis, Novo Nordisk, Pfizer*, Regeneron, Roche Diagnostic, Sanofi-Synthelabo - Consultant

Dr. Deepak Bhatt discloses the following relevant financial relationships with a commercial interest: Amarin, Amgen, AstraZeneca, Bristol-Myers Squibb, Chiesi, Eisai, Ethicon, Forest Laboratories, Ironwood, Ischemix, Lilly, Medtronic, Pfizer, Roche, Sanofi Aventis, The Medicines Company – Research Funding.

Dr. Peter Libby discloses the following relevant financial relationships with a commercial interest: Amgen, AstraZeneca, Esperion Therapeutics, Ionis Pharmaceuticals, Kowa Pharmaceuticals, Merck & Co., Inc., Novartis, Pfizer, Sanofi-Regeneron, Takeda Pharmaceuticals, XBiotech, Inc. – Consultant. Amgen, Athera Biotechnologies, Corvidia Therapeutics, DalCor Pharmaceuticals, Interleukin Genetics, Kowa Pharmaceuticals, Olatec Therapeutics, Medimmune, Novarti – Advisory Board.

Commercial Support: No commercial support was received for this activity.

Software Requirements: VuMedi Webinars supports the following web browsers (with enabled JavaScript™): Internet Explorer® versions 6.0, 7.0, 8.0, Mozilla Firefox versions 1.0, 2.0, 3.0, and Safari for Mac. Certain educational activities may require additional software to view multimedia, presentation or printable versions of their content. That software may be: Adobe Acrobat®, Adobe® Flash Player, Microsoft® Office PowerPoint, and Microsoft® Office Word.These activities will be marked as such and will provide links to the required software.

Copyright: Any and/or all materials are for the exclusive use of the faculty and participants of the live activity. Any copying, duplicating or reproducing of any and/or all materials by electronic, mechanical or other means for any purpose other than this enduring activity is strictly prohibited without prior written consent of the author of those materials.

Policy on Privacy and Confidentiality: For more information regarding VuMedi's Policy on Privacy and Confidentiality, please visit http://www.vumedi.com/pages/privacy/

To Contact our Accredited Provider: Ellen P. Seaback, CMP, CAE, CHCP
Executive Director
Office of Continuing Medical Education
UC Irvine Health School of Medicine
Irvine, California
eseaback@uci.edu
949.824.1150
http://www.meded.uci.edu/CME/

For questions regarding this activity, please contact VuMedi: cme@vumedi.com


1 Comment
Login to view comments. Click here to Login